{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:53:44Z","timestamp":1790610824421,"version":"4.1.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273323"],"award-info":[{"award-number":["82273323"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Leptomeningeal metastasis (LM) is an advanced complication of lung cancer with a poor prognosis. It remains unknown whether intrathecal pemetrexed (IP) can improve the outcomes of patients with LM from lung adenocarcinoma (LUAD). This study explored the efficacy of intrathecal pemetrexed (IP) and proteomic biomarkers in LM from LUAD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective survival analysis of 157 confirmed LM patients (54 IP vs 103 non-IP). To balance the baseline, propensity score matching (PSM) was implemented. We investigated clinical baseline characteristics and treatment factors to identify those influencing the outcomes of LM patients. Plasma and cerebrospinal fluid (CSF) samples underwent proteomic profiling using Olink Immuno-Oncology panels to identify IP response biomarkers and build a prediction model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After PSM, 82 patients were included in two matched cohort (41 IP vs 41 non-IP). IP treatment (HR\u2009=\u20090.427, P\u2009=\u2009.022) and ECOG performance status (HR\u2009=\u20092.737, P\u2009=\u2009.005) were independent predictors of overall survival (OS). Stratified analysis showed IP significantly improved OS in patients with poor performance status (ECOG 3-4: IP vs non-IP, 11.2 vs 2.5\u2009months, P\u2009=\u2009.0029). Proteomics revealed low plasma MCP-2 (AUC\u2009=\u20090.873) and high CSF ARG1 (AUC\u2009=\u20090.875) levels distinguished IP responders from nonresponders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>IP therapy improves OS in LUAD patients with LM, particularly offering significant benefit as salvage treatment for those with ECOG 3-4. Proteomic analysis suggests plasma MCP-2 and CSF ARG1 are promising predictive biomarkers for IP response. The small sample size in biomarker analysis may limit these findings, necessitating validation through multicenter studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf291","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T11:20:09Z","timestamp":1758540009000},"source":"Crossref","is-referenced-by-count":4,"title":["Intrathecal pemetrexed for leptomeningeal metastasis from lung adenocarcinoma: a clinical efficacy and multiplex liquid proteomics exploration study"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8320-2035","authenticated-orcid":false,"given":"Zhi","family":"Wang","sequence":"first","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan, 430022,","place":["China"]},{"name":"Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan, 430022,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Ding","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan, 430022,","place":["China"]},{"name":"Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan, 430022,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxia","family":"Zhou","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan, 430022,","place":["China"]},{"name":"Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan, 430022,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohua","family":"Kuang","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan, 430022,","place":["China"]},{"name":"Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan, 430022,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiguang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan, 430022,","place":["China"]},{"name":"Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan, 430022,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingjuan","family":"Chen","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan, 430022,","place":["China"]},{"name":"Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan, 430022,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Zhang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Neurology and Oncology Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing Simcere Medical Laboratory Science Co., Ltd , Nanjing, 210042,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghui","family":"Ge","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Neurology and Oncology Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing Simcere Medical Laboratory Science Co., Ltd , Nanjing, 210042,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqin","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Neurology and Oncology Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing Simcere Medical Laboratory Science Co., Ltd , Nanjing, 210042,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Tong","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan, 430022,","place":["China"]},{"name":"Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan, 430022,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaorong","family":"Dong","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan, 430022,","place":["China"]},{"name":"Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan, 430022,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,24]]},"reference":[{"key":"2025102208021663100_oyaf291-B1","doi-asserted-by":"crossref","first-page":"101624","DOI":"10.1016\/j.esmoop.2023.101624","article-title":"Leptomeningeal metastasis from solid tumours: EANO-ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"8","author":"Le Rhun","year":"2023","journal-title":"ESMO Open"},{"key":"2025102208021663100_oyaf291-B2","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1093\/neuonc\/noab101","article-title":"Epidemiology of brain metastases and leptomeningeal disease","volume":"23","author":"Lamba","year":"2021","journal-title":"Neuro Oncol"},{"key":"2025102208021663100_oyaf291-B3","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.3390\/biomedicines12081792","article-title":"Radiotherapy and systemic treatment for leptomeningeal disease","volume":"12","author":"Frechette","year":"2024","journal-title":"Biomedicines"},{"key":"2025102208021663100_oyaf291-B4","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41571-024-00970-3","article-title":"Leptomeningeal metastatic disease: new frontiers and future directions","volume":"22","author":"Ozair","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"2025102208021663100_oyaf291-B5","doi-asserted-by":"crossref","first-page":"2375521","DOI":"10.1080\/10717544.2024.2375521","article-title":"Drug delivery in leptomeningeal disease: navigating barriers and beyond","volume":"31","author":"Arshad","year":"2024","journal-title":"Drug Deliv"},{"key":"2025102208021663100_oyaf291-B6","doi-asserted-by":"crossref","first-page":"15330338221078429","DOI":"10.1177\/15330338221078429","article-title":"A retrospective study of intrathecal pemetrexed combined with systemic therapy for leptomeningeal metastasis of lung cancer","volume":"21","author":"Geng","year":"2022","journal-title":"Technol Cancer Res Treat"},{"key":"2025102208021663100_oyaf291-B7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1158\/1078-0432.CCR-22-1585","article-title":"Leptomeningeal metastasis from non-small cell lung cancer and current landscape of treatments","volume":"29","author":"Ozcan","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2025102208021663100_oyaf291-B8","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1016\/j.cllc.2022.11.011","article-title":"Safety, pharmacokinetic and clinical activity of intrathecal chemotherapy with pemetrexed via the ommaya reservoir for leptomeningeal metastases from lung adenocarcinoma: a prospective phase I study","volume":"24","author":"Li","year":"2023","journal-title":"Clin Lung Cancer"},{"key":"2025102208021663100_oyaf291-B9","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2217\/fon-2022-0926","article-title":"Cerebrospinal fluid-administered therapies for leptomeningeal metastases from solid tumors","volume":"19","author":"Baskaran","year":"2023","journal-title":"Future Oncol"},{"key":"2025102208021663100_oyaf291-B10","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s40264-021-01135-2","article-title":"Mechanisms, management and prevention of pemetrexed-related toxicity","volume":"44","author":"de Rouw","year":"2021","journal-title":"Drug Saf"},{"key":"2025102208021663100_oyaf291-B11","doi-asserted-by":"crossref","first-page":"e40703","DOI":"10.1016\/j.heliyon.2024.e40703","article-title":"Intrathecal pemetrexed improves survival outcomes in previously treated EGFR-mutant advanced non-small-cell lung cancer with leptomeningeal metastases","volume":"10","author":"Li","year":"2024","journal-title":"Heliyon"},{"key":"2025102208021663100_oyaf291-B12","doi-asserted-by":"crossref","first-page":"102384","DOI":"10.1016\/j.esmoop.2024.102384","article-title":"Efficacy and safety of intrathecal pemetrexed for TKI-failed leptomeningeal metastases from EGFR+ NSCLC: an expanded, single-arm, phase II clinical trial","volume":"9","author":"Fan","year":"2024","journal-title":"ESMO Open"},{"key":"2025102208021663100_oyaf291-B13","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00281-022-00980-2","article-title":"Proteomics to study cancer immunity and improve treatment","volume":"45","author":"Franciosa","year":"2023","journal-title":"Semin Immunopathol"},{"key":"2025102208021663100_oyaf291-B14","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/j.jtho.2016.06.029","article-title":"Leptomeningeal metastases in patients with NSCLC with EGFR mutations","volume":"11","author":"Li","year":"2016","journal-title":"J Thorac Oncol"},{"key":"2025102208021663100_oyaf291-B15","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1093\/neuonc\/noae103","article-title":"Leptomeningeal metastases from solid tumors: a Society for Neuro-Oncology and American Society of Clinical Oncology consensus review on clinical management and future directions","volume":"26","author":"Wilcox","year":"2024","journal-title":"Neuro Oncol"},{"key":"2025102208021663100_oyaf291-B16","doi-asserted-by":"crossref","first-page":"838","DOI":"10.3389\/fonc.2019.00838","article-title":"A pilot phase 1 study of intrathecal pemetrexed for refractory leptomeningeal metastases from non-small-cell lung cancer","volume":"9","author":"Pan","year":"2019","journal-title":"Front Oncol"},{"key":"2025102208021663100_oyaf291-B17","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.jtho.2021.04.018","article-title":"Efficacy and safety of intrathecal pemetrexed combined with dexamethasone for treating tyrosine kinase inhibitor-failed leptomeningeal metastases from EGFR-mutant NSCLC-a prospective, open-label, single-arm phase 1\/2 clinical trial (unique identifier: ChiCTR1800016615)","volume":"16","author":"Fan","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2025102208021663100_oyaf291-B18","first-page":"484","article-title":"Leptomeningeal metastases: a RANO proposal for response criteria","volume":"19","author":"Chamberlain","year":"2017","journal-title":"Neuro Oncol"},{"key":"2025102208021663100_oyaf291-B19","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s11916-023-01180-9","article-title":"The spectrum of headache in leptomeningeal metastases: a comprehensive review with clinical management guidelines","volume":"27","author":"Wilcox","year":"2023","journal-title":"Curr Pain Headache Rep"},{"key":"2025102208021663100_oyaf291-B20","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s11060-023-04483-4","article-title":"Effects of intrathecal pemetrexed on the survival of patients with leptomeningeal metastasis from lung adenocarcinoma: a propensity score matching analysis","volume":"165","author":"Hong","year":"2023","journal-title":"J Neurooncol"},{"key":"2025102208021663100_oyaf291-B21","doi-asserted-by":"crossref","first-page":"2290790","DOI":"10.1080\/2162402X.2023.2290790","article-title":"Cerebrospinal fluid immunological cytokines predict intracranial tumor response to immunotherapy in non-small cell lung cancer patients with brain metastases","volume":"13","author":"Li","year":"2024","journal-title":"Oncoimmunology"},{"key":"2025102208021663100_oyaf291-B22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3390\/diseases9010021","article-title":"Diagnostic and prognostic value of CEA and CA19-9 in colorectal cancer","volume":"9","author":"Lakemeyer","year":"2021","journal-title":"Diseases"},{"key":"2025102208021663100_oyaf291-B23","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.semcancer.2022.11.010","article-title":"Role of chemokines in HPV-induced cancers","volume":"87","author":"Israr","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"2025102208021663100_oyaf291-B24","doi-asserted-by":"crossref","first-page":"8412","DOI":"10.3390\/ijms21218412","article-title":"CC chemokines in a tumor: a review of pro-cancer and anti-cancer properties of the ligands of receptors CCR1, CCR2, CCR3, and CCR4","volume":"21","author":"Korbecki","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2025102208021663100_oyaf291-B25","doi-asserted-by":"crossref","first-page":"116014","DOI":"10.1016\/j.biopha.2023.116014","article-title":"The role of tumor-associated macrophages in lung cancer: from mechanism to small molecule therapy","volume":"170","author":"Zhou","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"2025102208021663100_oyaf291-B26","doi-asserted-by":"crossref","first-page":"e180893","DOI":"10.1172\/JCI180893","article-title":"Tumor initiating cells escape tumor immunity via CCL8 from tumor-associated macrophages in mice","volume":"135","author":"Chen","year":"2025","journal-title":"J Clin Invest"},{"key":"2025102208021663100_oyaf291-B27","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.immuni.2023.06.017","article-title":"Hypoxic niches attract and sequester tumor-associated macrophages and cytotoxic T cells and reprogram them for immunosuppression","volume":"56","author":"Sattiraju","year":"2023","journal-title":"Immunity"},{"key":"2025102208021663100_oyaf291-B28","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/cbin.10909","article-title":"MCP2 activates NF-\u03baB signaling pathway promoting the migration and invasion of ESCC cells","volume":"42","author":"Zhou","year":"2018","journal-title":"Cell Biol Int"},{"key":"2025102208021663100_oyaf291-B29","doi-asserted-by":"crossref","first-page":"6309","DOI":"10.1038\/onc.2016.161","article-title":"A CCL8 gradient drives breast cancer cell dissemination","volume":"35","author":"Farmaki","year":"2016","journal-title":"Oncogene"},{"key":"2025102208021663100_oyaf291-B30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40170-022-00301-z","article-title":"Arginase-1 inhibition reduces migration ability and metastatic colonization of colon cancer cells","volume":"11","author":"Wang","year":"2023","journal-title":"Cancer Metab"},{"key":"2025102208021663100_oyaf291-B31","doi-asserted-by":"crossref","first-page":"e009930","DOI":"10.1136\/jitc-2024-009930","article-title":"Arginase-1-specific T cells target and modulate tumor-associated macrophages","volume":"13","author":"Martinenaite","year":"2025","journal-title":"J Immunother Cancer"},{"key":"2025102208021663100_oyaf291-B32","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41392-023-01452-1","article-title":"Macrophages in immunoregulation and therapeutics","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"2025102208021663100_oyaf291-B33","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3389\/fnagi.2017.00176","article-title":"Targeting microglial activation states as a therapeutic avenue in Parkinson\u2019s disease","volume":"9","author":"Subramaniam","year":"2017","journal-title":"Front Aging Neurosci"},{"key":"2025102208021663100_oyaf291-B34","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.neuroscience.2020.03.008","article-title":"IL-4 switches microglia\/macrophage M1\/M2 polarization and alleviates neurological damage by modulating the JAK1\/STAT6 pathway following ICH","volume":"437","author":"He","year":"2020","journal-title":"Neuroscience"},{"key":"2025102208021663100_oyaf291-B35","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1177\/0271678X20951995","article-title":"Regulation of blood-brain barrier integrity by microglia in health and disease: a therapeutic opportunity","volume":"40","author":"Ronaldson","year":"2020","journal-title":"J Cereb Blood Flow Metab"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf291\/64372341\/oyaf291.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/10\/oyaf291\/64372341\/oyaf291.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/10\/oyaf291\/64372341\/oyaf291.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:02:27Z","timestamp":1761134547000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf291\/8262863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf291","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,9,24]]},"article-number":"oyaf291"}}